INmune Bio Inc (NASDAQ:INMB) CFO David J. Moss bought 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were acquired at an average cost of $5.65 per share, for a total transaction of $16,950.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

INMB traded up $0.29 during trading hours on Thursday, hitting $5.80. 34,167 shares of the company’s stock were exchanged, compared to its average volume of 37,992. INmune Bio Inc has a 12-month low of $5.06 and a 12-month high of $11.50. The stock’s 50 day moving average price is $8.41. The company has a quick ratio of 20.94, a current ratio of 20.94 and a debt-to-equity ratio of 0.01.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Monday, August 12th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.16. Research analysts forecast that INmune Bio Inc will post -0.75 earnings per share for the current year.

INMB has been the topic of several recent research reports. HC Wainwright initiated coverage on shares of INmune Bio in a research note on Wednesday. They set a “buy” rating and a $11.50 target price on the stock. Maxim Group reaffirmed a “buy” rating and set a $13.00 target price on shares of INmune Bio in a research note on Wednesday, August 14th.

An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc. increased its holdings in shares of INmune Bio Inc (NASDAQ:INMB) by 1,556.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,048 shares of the company’s stock after purchasing an additional 2,864 shares during the period. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 as of its most recent SEC filing. 0.46% of the stock is currently owned by institutional investors.

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Recommended Story: What is an economic bubble?

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with's FREE daily email newsletter.